Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-207 in Advanced EGFR-Mutant NSCLC
NCT05920135Phase 2Active, not recruiting
- Sponsor
- Bridge Biotherapeutics
- Start
- Sep 2023
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of BBT-207 in non-small cell lung cancer (NSCLC), sponsored by Bridge Biotherapeutics. Started Sep 2023; status: active, not recruiting.
02
Drugs
BBT-207
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05920135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05920135.